Skip to main content
Premium Trial:

Request an Annual Quote

Codon Devices Reportedly Shuts Down

NEW YORK (GenomeWeb News) – Codon Devices is reportedly shutting down its operations, according to an article posted on website of The Boston Globe on Friday.

Calls to Codon were not returned to GenomeWeb Daily News to confirm the report.

The Cambridge, Mass.-based firm markets its synthetic biology products and design services, including its BioFab production platform, to clients in the pharmaceutical, biotechnology, institutional, and bioenergy fields. The BioFab platform combines informatics and proprietary algorithms, automated technology, and biochemical protocols for use in designing and building genetic sequences.

Codon raised $11 million in a round of private financing last year through some well-known life science venture capital firms including Alloy Ventures, Flagship Ventures, Highland Capital Partners, Khosla Ventures, Kleiner Perkins Caufield & Byers, and Tactics II Ventures. The company had raised $20 million in December 2006.

According to the Globe article, Codon's board decided last week to shut down operations after the firm failed to raise additional funds.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.